Atractylodes Macrocephala Root

Dosage for Atractylodes Macrocephala Root allergenic extract is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels.

Diagnostic Testing

• Skin Prick Test (SPT): Usually, one drop of the 1:10 or 1:20 w/v extract is applied to the skin, followed by a prick or scratch. Results are read after 15 to 20 minutes.
• Intradermal Testing: If the SPT is negative but clinical suspicion remains high, a 1:100 to 1:1000 dilution may be injected intradermally (0.02 mL) to create a small bleb.

Immunotherapy (SCIT)

• Build-up Phase: Injections typically start at a very low concentration (e.g., 0.01 mL of a 1:10,000 dilution) and increase weekly or bi-weekly until a 'maintenance dose' is reached.
• Maintenance Phase: Once the maintenance dose is achieved (often 0.5 mL of the most concentrated vial), injections are spaced out to every 2 to 4 weeks.

Atractylodes Macrocephala Root extract may be used in children, but the dosage follows the same individualized titration as in adults. Pediatric patients are at a higher risk for systemic reactions, and the clinician must exercise extreme caution. There is no specific age-based dosage; rather, it is based on the 'end-point' of skin reactivity.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the proteins are primarily degraded proteolytically. However, the patient's overall health must be stable before administration.

Hepatic Impairment

No dosage adjustments are necessary. Hepatic function does not significantly impact the clearance of injected allergenic proteins.

Elderly Patients

Elderly patients may have reduced skin reactivity, leading to potential false negatives in diagnostic testing. Furthermore, the risk of cardiovascular complications during a systemic reaction (anaphylaxis) is higher in this population. Caution is advised if the patient is taking beta-blockers or ACE inhibitors.

This extract is never for self-administration. It must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

• Administration: Subcutaneous injection is the standard for immunotherapy. It should be given in the posterior aspect of the upper arm.
• Observation: Patients must remain in the clinic for at least 30 minutes following an injection to monitor for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep away from light to prevent protein denaturation.

In immunotherapy, if a dose is missed, the next dose may need to be reduced depending on how much time has passed. If more than 4 weeks have passed since the last injection, the clinician may need to 'back-step' the dose to a lower concentration to ensure safety.

An overdose in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level, leading to a systemic reaction.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (0.3 mg for adults), followed by antihistamines, corticosteroids, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency without medical guidance. The risk of a severe reaction is highest when the dose is increased or if a dose is given after a long hiatus.

The most frequent side effects associated with Atractylodes Macrocephala Root extract are localized to the site of administration.

• Local Wheal and Flare: During diagnostic testing, a red, itchy bump is the expected result in sensitized individuals. This typically resolves within 1 to 2 hours.
• Injection Site Swelling: In immunotherapy, patients often experience swelling and redness at the injection site (the 'local reaction'). If the swelling is smaller than the size of a half-dollar, it is generally considered a normal part of the treatment.
• Pruritus (Itching): Intense itching at the site of the prick or injection is very common and can be managed with topical cold packs.

• Large Local Reactions (LLR): Swelling that exceeds 5 cm in diameter. This may persist for 24 to 48 hours and may require oral antihistamines.
• Fatigue: Some patients report feeling unusually tired for a few hours following an allergy injection.
• Nasal Congestion: Mild sneezing or a runny nose may occur shortly after administration as a minor systemic response.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Gastrointestinal Distress: Nausea or abdominal cramping, which can be an early sign of a systemic allergic reaction.
• Syncope (Fainting): Often a vasovagal response to the needle rather than the extract itself, but must be distinguished from anaphylactic shock.

> Warning: Stop taking Atractylodes Macrocephala Root and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Difficulty Breathing: Wheezing, chest tightness, or a sensation of the throat closing.
• Hypotension: A sudden drop in blood pressure, leading to dizziness, confusion, or loss of consciousness.
• Angioedema: Significant swelling of the lips, tongue, or face.
• Rapid/Weak Pulse: Tachycardia associated with a feeling of impending doom.
• Cyanosis: A bluish tint to the lips or fingernails, indicating lack of oxygen.

There are no known long-term 'toxic' effects of Atractylodes Macrocephala Root extract because it is not a drug that accumulates in tissues. The primary long-term risk is the development of new sensitivities or the persistence of local reactions. However, for most patients, the long-term effect is the desired reduction in allergic symptoms (immunological tolerance).

While Atractylodes Macrocephala Root extract itself may not have a specific 'branded' black box warning, the entire class of Allergenic Extracts carries a general warning regarding the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma are at higher risk. Extracts should only be administered by clinicians trained in the management of anaphylaxis. Patients should be observed for at least 30 minutes. Epinephrine must be available for immediate use.

Report any unusual symptoms to your healthcare provider. Even a mild systemic reaction (like a few hives) must be reported before your next dose, as it may predict a more severe reaction in the future.

Atractylodes Macrocephala Root extract is a potent biological agent. Its use is restricted to diagnostic and therapeutic protocols under the supervision of an allergist. Patients must be aware that even if they have tolerated previous injections, the risk of a systemic reaction is always present. Factors such as exercise, hot showers, or acute illness shortly after an injection can increase the rate of absorption and the risk of a reaction.

No specific FDA black box warning exists for Atractylodes Macrocephala Root specifically, but as noted in the side effects section, the class-wide warning for allergenic extracts applies. This warning emphasizes that these products are intended for use only by physicians experienced in administering allergenic extracts and that patients must be observed for at least 30 minutes post-injection.

• Anaphylaxis Risk: This is the most significant risk. Patients must be educated on the signs of anaphylaxis and may be required to carry an epinephrine auto-injector (e.g., EpiPen).
• Asthma Status: Patients with uncontrolled or severe asthma should not receive immunotherapy, as they are at a much higher risk of fatal bronchospasm during a systemic reaction.
• Asteraceae Cross-Reactivity: Patients with known severe allergies to ragweed, dandelion, or chamomile may have heightened sensitivity to Atractylodes Macrocephala Root. A careful history of botanical allergies is essential.
• Cardiovascular Health: Patients with pre-existing heart disease may not tolerate the stress of a systemic reaction or the effects of the epinephrine required to treat it.

• Peak Flow Meter: For asthmatic patients, a peak flow reading should be taken before each injection to ensure their lung function is stable.
• Vitals Monitoring: Blood pressure and heart rate should be checked if the patient feels unwell after administration.
• Skin Assessment: The injection site must be inspected for large local reactions before the patient leaves the clinic and again before the next scheduled dose.

Generally, Atractylodes Macrocephala Root does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.

Alcohol should be avoided on the day of an allergy injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the speed at which the allergen enters the bloodstream, potentially increasing the risk of a systemic reaction.

Immunotherapy is typically a 3-to-5-year commitment. If a patient decides to stop treatment early, there is no 'withdrawal' syndrome, but the allergic symptoms are likely to return. If treatment is interrupted for more than a few weeks, it cannot be restarted at the previous dose; a 'dose reduction' protocol must be followed to prevent anaphylaxis.

> Important: Discuss all your medical conditions with your healthcare provider before starting Atractylodes Macrocephala Root. Be sure to mention if you are taking any heart medications or have a history of asthma.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are generally contraindicated in patients receiving allergenic extracts. The reason is not a direct interaction with the extract, but rather that beta-blockers interfere with the action of epinephrine. If a patient on a beta-blocker has an anaphylactic reaction, the standard doses of epinephrine may be ineffective, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions to allergenic extracts or worsen the severity of the reaction by interfering with the body's natural compensatory mechanisms (like the renin-angiotensin system).
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, which could be problematic if epinephrine is needed to treat a reaction, leading to a hypertensive crisis.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular response to epinephrine.

• Antihistamines (e.g., Loratadine, Cetirizine): These must be discontinued for 3 to 7 days prior to diagnostic skin testing. Antihistamines block the H1 receptors in the skin, which will prevent the 'wheal and flare' reaction even if the patient is allergic, leading to a false-negative result. However, they are often continued during the immunotherapy phase to reduce local itching.
• Systemic Corticosteroids: Long-term use of high-dose steroids can suppress skin reactivity, potentially affecting diagnostic results.

• Alcohol: As mentioned, alcohol increases peripheral blood flow and can accelerate the systemic absorption of the injected extract, increasing the risk of a reaction.
• Spicy Foods: In some individuals, very spicy foods can trigger flushing or mild histamine release, which might complicate the assessment of a reaction site.

• Other Asteraceae Supplements: Taking supplements containing Echinacea, Milk Thistle, or Dandelion may increase the 'allergic load' and potentially lower the threshold for a reaction to the Atractylodes extract.
• St. John's Wort: While primarily a CYP inducer, its effects on photosensitivity and general immune modulation mean it should be discussed with an allergist.

• Skin Tests: The extract itself is the tool for the test. No other common lab tests (like CBC or Chem-7) are known to be affected by the administration of this extract.
• Total IgE: Treatment with the extract over time may cause a transient increase in total IgE levels before they eventually decline during the maintenance phase.

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug or the treatment of its side effects) rather than pharmacokinetic (affecting how the drug is broken down).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for blood pressure or heart rhythm.

Atractylodes Macrocephala Root extract must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted are at an unacceptably high risk of fatal bronchospasm during an allergic reaction.
2. 2Previous Severe Systemic Reaction: If a patient has had a life-threatening reaction to this specific extract in the past that could not be managed by dose adjustment.
3. 3Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis with epinephrine.
4. 4Acute Infection or Fever: Administration during an illness can lower the threshold for a systemic reaction.

These conditions require a careful risk-benefit analysis by the physician:

• Pregnancy: While not directly toxic, the risk of a systemic reaction (and the resulting hypoxia to the fetus) makes starting new immunotherapy during pregnancy inadvisable. If a patient is already on a stable maintenance dose, it may sometimes be continued.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to allergenic extracts.
• Malignancy: The immune system's focus should generally not be diverted by immunotherapy during active cancer treatment.
• Young Children (<5 years old): The difficulty of communicating symptoms of a reaction and the technical challenges of administration make this a relative contraindication.

Patients should be screened for sensitivity to other members of the Asteraceae (Compositae) family. This includes:

• Ragweed (Ambrosia)
• Chrysanthemums
• Marigolds
• Daisies
• Echinacea
• Artichokes

If a patient has a known 'anaphylactic-level' allergy to any of these, the initial dose of Atractylodes Macrocephala Root must be significantly reduced.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Atractylodes Macrocephala Root.

Atractylodes Macrocephala Root extract is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not teratogenicity (birth defects) from the extract itself, but the danger of maternal anaphylaxis. A severe allergic reaction can lead to maternal hypotension and uterine hypoperfusion, resulting in fetal hypoxia (lack of oxygen) and potential fetal death.

• Initiation: It is standard clinical practice not to start new allergy testing or immunotherapy during pregnancy.
• Maintenance: If a woman becomes pregnant while on a stable maintenance dose that she is tolerating well, the clinician may choose to continue the dose (but not increase it) after discussing the risks.

It is not known whether the protein components of Atractylodes Macrocephala Root extract are excreted in human milk. However, because these are large proteins that would likely be digested in the infant's gut, the risk to a nursing infant is considered low. The main consideration is the mother's stability and the risk of a reaction during the procedure.

Allergenic extracts are used in children, but caution is paramount. Children under the age of 5 may have difficulty articulating the early symptoms of a systemic reaction (such as an 'itchy throat' or 'funny taste in the mouth').

• Dosing: Dosing is not based on weight but on immunological sensitivity.
• Growth: There is no evidence that allergenic extracts affect growth or development.

In patients over 65, the clinician must balance the benefits of allergy treatment against the risks of co-morbidities.

• Cardiovascular Risk: Elderly patients are more likely to have underlying CAD (Coronary Artery Disease), making them poor candidates for epinephrine if a reaction occurs.
• Skin Reactivity: Reduced skin turgor and mast cell density in the elderly can lead to smaller wheal sizes, potentially leading to under-diagnosis.

Renal impairment does not significantly alter the clearance of allergenic proteins. However, patients with end-stage renal disease (ESRD) often have altered immune profiles and may be more prone to inflammatory responses. No specific GFR-based adjustments are published, but clinical monitoring should be intensified.

No adjustments are required for patients with liver disease. The liver is not the primary site of clearance for these biological extracts.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant, planning to become pregnant, or have underlying heart or lung conditions.

Atractylodes Macrocephala Root allergenic extract functions as an immunomodulator. At the molecular level, the extract contains a variety of proteins and glycoproteins that serve as epitopes (the part of an antigen that is recognized by the immune system).

In the diagnostic phase, these epitopes bind to IgE antibodies on the surface of sensitized mast cells and basophils. This binding causes the high-affinity IgE receptor (FcεRI) to aggregate, initiating a signaling cascade that involves tyrosine kinases (like Syk). This results in the release of pre-formed mediators (histamine) and the synthesis of new mediators (prostaglandins and leukotrienes), causing the clinical wheal and flare.

In the therapeutic phase (immunotherapy), the mechanism shifts. Repeated exposure to the antigen induces the production of Regulatory T-cells (Tregs). These cells secrete IL-10 and TGF-beta, which suppress the Th2 allergic response. Furthermore, B-cells are signaled to switch from producing IgE to producing IgG4. IgG4 acts as a 'blocking antibody,' intercepting the allergen before it can reach the IgE on mast cells.

• Onset of Action: For skin testing, the onset is immediate (15-20 minutes). For immunotherapy, the onset of clinical benefit is slow, often taking 6 to 12 months of regular injections.
• Duration of Effect: The diagnostic effect is transient. The therapeutic effect of immunotherapy can be long-lasting, often persisting for years after the 3-5 year treatment course is completed.
• Tolerance: The goal of treatment is the development of 'immunological tolerance,' which is the opposite of drug tolerance; it is a beneficial state where the body no longer overreacts to the allergen.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Intradermal) |

| Protein Binding | Primarily to IgE and IgG4 antibodies |

| Half-life | Variable (Proteins degraded within hours to days) |

| Tmax | 30-60 minutes for systemic absorption |

| Metabolism | Proteolysis (Protease enzymes) |

| Excretion | Renal (as small peptide fragments) |

• Composition: A complex mixture of proteins, polysaccharides, and secondary metabolites (such as atractylenolide I, II, and III).
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for the various protein fractions.
• Solubility: Soluble in aqueous solutions and phenolated saline diluents.

Atractylodes Macrocephala Root belongs to the class of Allergenic Extracts. It is specifically grouped under non-standardized extracts, meaning its potency is determined by the manufacturer's consistent process rather than a standardized bioassay. It is related to other botanical extracts like Ambrosia artemisiifolia (Ragweed) and Artemisia vulgaris (Mugwort).